Pivotal Safety And Efficacy Results From Transcend Nhl 001, A Multicenter Phase 1 Study Of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory ( R/R) Large B Cell Lymphomas

Background: CAR T cell therapies have demonstrated high response rates in patients (pts) with R/R B cell NHL. Liso-cel is an investigational anti-CD19, defined composition, 4-1BB CAR T cell product administered at target doses of CD4+ and CD8+ CAR T cells. The seamless phase 1 TRANSCEND NHL 001 study evaluated liso-cel in pts with R/R large B cell NHL (NCT02631044). We present data with long-term follow-up from pts treated in the DLBCL cohort.